BioPharma

We need the capital and creativity of the private sector to take on the coronavirus.

COVID-19 response for Pharma companies.

Britain’s antitrust watchdog said it has suspended two investigations into pharmaceutical companies that it suspects of illegally colluding on the price of drugs.

The move, which will also reset copay cards to the same monthly $35 level, comes amid ongoing angst over the cost of the diabetes treatment.

The concern about the dependency of the US supply chain on nations such as China has been known about for some time.

Drugmaker Eli Lilly said it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the U.S.

America’s biopharmaceutical companies have joined forces to fight COVID-19.

Operational considerations for 2020

CNBC's Meg Tirrell reports that President Trump spoke with pharmaceutical executives regarding the response to COVID-19.

Pfizer, AbbVie, Novartis and other pharma companies are pledging millions in COVID-19 relief funds to help healthcare workers, patients and communities.

The settlement resolves allegations that MiMedx knowingly submitted false statements and disclosures to the VA regarding MiMedx’s commercial pricing practices.

How will pharma price their products against COVID-19?

Pharma companies are rushing to be the first to develop a vaccine for COVID-19. No sooner did they begin than officials and the public began wondering, “how will we pay for these treatments?”

The $2.2 trillion coronavirus relief bill that Congress hastily passed and Donald Trump signed into law deliberately creates new price gouging opportunities for drug companies.